The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent.
Mengjin HuXiaojin GaoJingang YangYue-Jin YangPublished in: Journal of clinical medicine (2022)
Among patients treated with DESs, 3-month DAPT followed by P2Y12 inhibitor monotherapy may be the optimal antiplatelet strategy, while DAPT beyond 1 year reduces myocardial infarction at the expense of increased major bleeding.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- atrial fibrillation
- coronary artery bypass grafting
- heart failure
- left ventricular
- combination therapy
- coronary artery bypass
- open label
- randomized controlled trial
- study protocol
- double blind